PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
RLAY vs. RXRX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between RLAY and RXRX is 0.52, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.00.5

Performance

RLAY vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Relay Therapeutics, Inc. (RLAY) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

-85.00%-80.00%-75.00%-70.00%JulyAugustSeptemberOctoberNovemberDecember
-87.24%
-80.73%
RLAY
RXRX

Key characteristics

Sharpe Ratio

RLAY:

-0.72

RXRX:

-0.42

Sortino Ratio

RLAY:

-1.31

RXRX:

-0.15

Omega Ratio

RLAY:

0.86

RXRX:

0.98

Calmar Ratio

RLAY:

-0.65

RXRX:

-0.42

Martin Ratio

RLAY:

-1.49

RXRX:

-0.79

Ulcer Index

RLAY:

40.63%

RXRX:

45.90%

Daily Std Dev

RLAY:

83.40%

RXRX:

85.82%

Max Drawdown

RLAY:

-93.24%

RXRX:

-88.97%

Current Drawdown

RLAY:

-93.24%

RXRX:

-85.41%

Fundamentals

Market Cap

RLAY:

$753.22M

RXRX:

$2.77B

EPS

RLAY:

-$2.61

RXRX:

-$1.54

Total Revenue (TTM)

RLAY:

$10.01M

RXRX:

$65.18M

Gross Profit (TTM)

RLAY:

$5.87M

RXRX:

$1.96M

EBITDA (TTM)

RLAY:

-$389.45M

RXRX:

-$355.84M

Returns By Period

In the year-to-date period, RLAY achieves a -62.22% return, which is significantly lower than RXRX's -38.84% return.


RLAY

YTD

-62.22%

1M

-10.73%

6M

-40.06%

1Y

-61.34%

5Y*

N/A

10Y*

N/A

RXRX

YTD

-38.84%

1M

-0.17%

6M

-31.86%

1Y

-38.72%

5Y*

N/A

10Y*

N/A

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

RLAY vs. RXRX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Relay Therapeutics, Inc. (RLAY) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for RLAY, currently valued at -0.72, compared to the broader market-4.00-2.000.002.00-0.72-0.42
The chart of Sortino ratio for RLAY, currently valued at -1.31, compared to the broader market-4.00-2.000.002.004.00-1.31-0.15
The chart of Omega ratio for RLAY, currently valued at 0.86, compared to the broader market0.501.001.502.000.860.98
The chart of Calmar ratio for RLAY, currently valued at -0.68, compared to the broader market0.002.004.006.00-0.68-0.42
The chart of Martin ratio for RLAY, currently valued at -1.49, compared to the broader market-5.000.005.0010.0015.0020.0025.00-1.49-0.79
RLAY
RXRX

The current RLAY Sharpe Ratio is -0.72, which is lower than the RXRX Sharpe Ratio of -0.42. The chart below compares the historical Sharpe Ratios of RLAY and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.80-0.60-0.40-0.200.000.200.400.60JulyAugustSeptemberOctoberNovemberDecember
-0.72
-0.42
RLAY
RXRX

Dividends

RLAY vs. RXRX - Dividend Comparison

Neither RLAY nor RXRX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

RLAY vs. RXRX - Drawdown Comparison

The maximum RLAY drawdown since its inception was -93.24%, roughly equal to the maximum RXRX drawdown of -88.97%. Use the drawdown chart below to compare losses from any high point for RLAY and RXRX. For additional features, visit the drawdowns tool.


-90.00%-85.00%-80.00%-75.00%JulyAugustSeptemberOctoberNovemberDecember
-89.05%
-85.41%
RLAY
RXRX

Volatility

RLAY vs. RXRX - Volatility Comparison

The current volatility for Relay Therapeutics, Inc. (RLAY) is 21.12%, while Recursion Pharmaceuticals, Inc. (RXRX) has a volatility of 35.51%. This indicates that RLAY experiences smaller price fluctuations and is considered to be less risky than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%JulyAugustSeptemberOctoberNovemberDecember
21.12%
35.51%
RLAY
RXRX

Financials

RLAY vs. RXRX - Financials Comparison

This section allows you to compare key financial metrics between Relay Therapeutics, Inc. and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2024 PortfoliosLab